Compare

ANI Pharmaceuticals/$ANIP

1D1W1M3M6MYTD1Y5YMAX

About ANI Pharmaceuticals

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Ticker
$ANIP
Sector
Health
Primary listing
NASDAQ
Employees
970

ANIP Metrics

BasicAdvanced
$1.5B
14.28
$5.00
0.47
-

What the Analysts think about ANIP

Analyst ratings (Buy, Hold, Sell) for ANI Pharmaceuticals stock.
Analyst projections of the future price of ANI Pharmaceuticals stock.

Bulls say / Bears say

Third-quarter revenue rose 27.6% year on year and adjusted EBITDA rose 39.8%; ANI also raised its 2026 adjusted EBITDA and EPS guidance. That points to strong earnings momentum despite lowering Cortrophin’s sales outlook. (ANI Pharmaceuticals)
Generics revenue grew 10.7% in the third quarter, and ANI had launched 16 new generic products year to date. Continued launches could broaden growth beyond its flagship rare-disease drug. (ANI Pharmaceuticals)
ANI’s proposed Egetis acquisition would add EMCITATE, the first and only approved treatment for MCT8 deficiency, with potential peak sales above $300 million and patent protection into 2045. If the offer closes and the launch succeeds, it could add a long-lived rare-disease growth driver. (ANI Pharmaceuticals)
ANI cut its 2026 Cortrophin revenue outlook to $480–500 million from $520–540 million after sales conversion lagged, citing capacity constraints in its specialty-pharmacy network. The gap between patient demand and patients starting therapy could hold back its key growth engine. (ANI Pharmaceuticals, The Motley Fool)
The proposed Egetis deal adds earnings and execution risk: its estimated enterprise value is about $434 million after expected proceeds from a priority review voucher sale, and management expects the acquisition to dilute adjusted EPS in year one as it invests in the US launch. (ANI Pharmaceuticals, The Motley Fool)
The retina franchise has shown uneven sales: ILUVIEN and YUTIQ revenue fell 16.1% year on year in Q2, while Q3 ILUVIEN revenue rose 34.1% partly because of the timing of international shipments. This makes it a less predictable counterweight to Cortrophin. (SEC, ANI Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.

ANIP Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

ANIP Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.